Tagged with Strategy,

Japan Japanese firm Kirin, part of the Mitsubishi Group and best known for its brewing operations, has pledged to invest JPY 100 billion (USD 870 million) into its healthcare/pharma operations amid a slowdown in the Japanese beer market.   Beer Today, Gone Tomorrow Japan’s rapidly ageing population and the effects of…

Spain Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The Italian executive reflects on his first few months at the helm, the cumulative experience of Almirall’s management board, the global…

Italy Ipsen’s Stephane Brocker discusses a transformational period for the iconic French mid-cap in recent years, how this has played out in Italy, and emergent trends – such as hybrid digital/in-person physician interactions – that have emerged from the COVID-19 pandemic period. Brocker also touches on Italy’s relevance to the global…

Spain Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree shift that entailed the divestment of its generics portfolio, new affiliates across the world, and a more focused product pipeline.…

Italy In a wide-ranging conversation, veteran general manager of Teva’s Italian Cluster Hubert Puech d’Alissac explores the reasons for the company’s growth in the region to become the generic market leader, post-COVID changes to the pharma industry, and the state of private-public relationships in Europe. Furthermore, d’Alissac touches on the responsibility…

Spain Merck’s general manager for Spain, Miguel Fernández Alcalde, speaks about the company’s shift towards becoming a global specialty innovator, what it means for their portfolio, and explains the group’s broad footprint in Spain, where it maintains three manufacturing sites. In addition, Fernández analyses the Spanish pharma market and what he…

Global Drawing on the findings of EY’s recently published life sciences M&A firepower report, EY Global Life Sciences Deals Leader Subin Baral makes the case for big biopharmas to seek out alliances and partnerships as an alternative to M&A and lists ten considerations that these firms should bear in mind if…

Italy   In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s third largest in Europe and sixth largest globally. Giese also touches on ensuring the affiliate’s product launch readiness, consistently increasing…

Spain STADA’s general manager for Spain, Mar Fabregas, reveals how the acquisition of parts of GSK and Sanofi’s portfolio is helping the global generics company better compete in consumer health. In addition, she analyses the biosimilars market in Spain, where the company recently launched Bevacizumab, and comments on the importance of…

Italy Lilly’s president and general manager for its Italy hub, Huzur Devletsah, explains the company’s broad footprint in the country – where Lilly maintains a large manufacturing site that produces over half of their global insulin output and from which it oversees 28 countries. In addition, she comments on the upcoming…

Italy Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in the early studies of remdesivir as a treatment against severe COVID-19 disease; how Gilead is working to eliminate viral Hepatitis…

Saudi Arabia Saudi Chemical Company Holding (SCCH), Saudi Arabia’s leading manufacturer of civil and military explosives, has been expanding its pharma sector footprint in recent years. Today, the company has capabilities across pharma distribution through SITCO Pharma, manufacturing (both for its own products and as a contract manufacturing organisation (CMO)) via AJA…